BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18615774)

  • 1. New approaches to the treatment of human herpesvirus 8-associated disease.
    Casper C
    Rev Med Virol; 2008; 18(5):321-9. PubMed ID: 18615774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in Developing Treatments of Kaposi's Sarcoma Herpesvirus-Related Diseases.
    Naimo E; Zischke J; Schulz TF
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.
    Uldrick TS; Polizzotto MN; Yarchoan R
    Curr Opin Oncol; 2012 Sep; 24(5):495-505. PubMed ID: 22729151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.
    Sullivan RJ; Pantanowitz L; Casper C; Stebbing J; Dezube BJ
    Clin Infect Dis; 2008 Nov; 47(9):1209-15. PubMed ID: 18808357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient.
    Ozbalak M; Tokatlı I; Özdemirli M; Tecimer T; Ar MC; Örnek S; Koroglu A; Laleli Y; Ferhanoglu B
    Eur J Haematol; 2013 Nov; 91(5):467-9. PubMed ID: 23865480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
    Uldrick TS; Polizzotto MN; Aleman K; O'Mahony D; Wyvill KM; Wang V; Marshall V; Pittaluga S; Steinberg SM; Tosato G; Whitby D; Little RF; Yarchoan R
    Blood; 2011 Jun; 117(26):6977-86. PubMed ID: 21487108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human herpesvirus 8 (HHV-8) in the pathogenesis of Kaposi's sarcoma and other diseases.
    Humphrey RW; Davis DA; Newcomb FM; Yarchoan R
    Leuk Lymphoma; 1998 Jan; 28(3-4):255-64. PubMed ID: 9517497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.
    Du MQ; Bacon CM; Isaacson PG
    J Clin Pathol; 2007 Dec; 60(12):1350-7. PubMed ID: 18042691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-associated multicentric Castleman disease.
    Oksenhendler E
    Curr Opin HIV AIDS; 2009 Jan; 4(1):16-21. PubMed ID: 19343828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I treat HHV8/KSHV-related diseases in posttransplant patients.
    Riva G; Luppi M; Barozzi P; Forghieri F; Potenza L
    Blood; 2012 Nov; 120(20):4150-9. PubMed ID: 22968461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): epidemiology and pathogenesis.
    Schulz TF
    J Antimicrob Chemother; 2000 Apr; 45 Suppl T3():15-27. PubMed ID: 10855768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine-Targeted Therapeutics for KSHV-Associated Disease.
    Alomari N; Totonchy J
    Viruses; 2020 Sep; 12(10):. PubMed ID: 32998419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Favorable outcome of Castleman's disease treated with oral valganciclovir].
    Valencia ME; Moreno V; Martínez P; Casado I
    Med Clin (Barc); 2005 Sep; 125(10):399. PubMed ID: 16185555
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma.
    Casper C; Wald A
    Curr Top Microbiol Immunol; 2007; 312():289-307. PubMed ID: 17089802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.
    Lurain K; Yarchoan R; Uldrick TS
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):75-88. PubMed ID: 29157621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment.
    Gantt S; Casper C
    Curr Opin Infect Dis; 2011 Aug; 24(4):295-301. PubMed ID: 21666458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs.
    Humphrey RW; O'Brien TR; Newcomb FM; Nishihara H; Wyvill KM; Ramos GA; Saville MW; Goedert JJ; Straus SE; Yarchoan R
    Blood; 1996 Jul; 88(1):297-301. PubMed ID: 8704186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaposi's sarcoma-associated herpesvirus: the role of lytic replication in targeted therapy.
    Andrei G; Snoeck R
    Curr Opin Infect Dis; 2015 Dec; 28(6):611-24. PubMed ID: 26524334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.
    Casper C; Krantz EM; Corey L; Kuntz SR; Wang J; Selke S; Hamilton S; Huang ML; Wald A
    J Infect Dis; 2008 Jul; 198(1):23-30. PubMed ID: 18491970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Kaposi sarcoma and multicentric Castleman's disease in a heart transplant recipient.
    Patel A; Bishburg E; Zucker M; Tsang P; Nagarakanti S; Sabnani I
    Heart Lung; 2014; 43(6):506-9. PubMed ID: 25169666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.